person · Reporting owner
Babineaux-Fontenot Claire
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | April 24, 2026 | April 28, 2026 |
| Charah Solutions, Inc.CHRA · Entity 111345 | Director | August 16, 2018 | August 20, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 24, 2026 · Filed April 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 7,603 |
Reported balance
After 2026-04-24 transaction · row 1
1 source rowRow 1 · 2026-04-24 · Grant · Acquired 2,286 · Balance 7,603 F1: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Charah Solutions, Inc.
Report date August 16, 2018 · Filed August 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,334 |
Reported balance
After 2018-08-16 transaction · row 1
1 source rowRow 1 · 2018-08-16 · Grant · Acquired 8,334 · Balance 8,334 F1: Acquisition consists of an award of restricted stock units granted under the Charah Solutions, Inc. 2018 Omnibus Incentive Plan. |
| Common StockSEC Table I · non-derivative | IndirectBy Husband | 2,500 |
Reported balance
Holding disclosure · report date 2018-08-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,500 F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquisition consists of an award of restricted stock units granted under the Charah Solutions, Inc. 2018 Omnibus Incentive Plan.
F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 24, 2026 Filed Apr 28, 2026 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001736637-26-000002 · form4-04282026_100459.xml · nonDerivative · entry 1 Babineaux-Fontenot Claire · CIK 0001736637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,603 F1 · shares: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011516 · form4-04292025_090438.xml · nonDerivative · entry 1 Babineaux-Fontenot Claire · CIK 0001736637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,317 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 21:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011786 · form4-04302024_090435.xml · nonDerivative · entry 1 Babineaux-Fontenot Claire · CIK 0001736637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,682 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 28, 2023 Filed May 2, 2023 23:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007127 · form4-05022023_110537.xml · nonDerivative · entry 1 Babineaux-Fontenot Claire · CIK 0001736637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,816 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 19:12 UTC | Charah Solutions, Inc. CHRA · Entity 111345 | GrantCommon Stock | 8,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-022829 · doc4.xml · nonDerivative · entry 1 Babineaux-Fontenot Claire · CIK 0001736637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,334 F1 · kind: Acquisition consists of an award of restricted stock units granted under the Charah Solutions, Inc. 2018 Omnibus Incentive Plan. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 21:05 UTC | Charah Solutions, Inc. CHRA · Entity 111345 | PurchaseCommon Stock | 2,500 | $12.00 | $30,000.00 |
DisclosureSEC source: 0000899243-18-017538 · doc4.xml · nonDerivative · entry 1 Babineaux-Fontenot Claire · CIK 0001736637 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Husband Disclosed balance after: 2,500 F1 · kind: These shares of common stock were purchased in the directed share program conducted in connection with Charah Solutions, Inc.'s initial public offering. F2 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.